EDITORIAL SECTIONS
RESEARCH & DEVELOPMENT
Adopting the Power of AI to Drug Development Projects
A tremendous amount of documentation is created throughout the clinical trial lifecycle
CLINICAL TRIALS
Real-world Evidence
Hearing the diagnosis from the doctor that your child has spinal muscular atrophy SMA
MANUFACTURING
Just in Time Manufacturing Creating more sustainable supply chains
Drug development has transformed immeasurably over the past decade Even before the Covid pandemic and the conflict in Ukraine
Information Technology
Challenges and Advantages of Using Artificial Intelligence in Pharma
Many advanced largescale AI initiatives still need to be proved successful in Pharma
KNOWLEDGE BANK
Interviews
mRNA Platforms as Diagnostics and Therapeutics for Human Infertility Treatments
Associate Professor, Department of Biology, Khalifa University
Junaid Kashir is an Associate Professor in the Department of Biology at Khalifa University and
has previously chaired multiple researchadministrative committees He has been heavily
involved in multiple programs for training graduate clinical embryology students Dr Kashirs
research aims to develop therapeuticdiagnostic interventions to treat infertility and understand
embryology
Articles
Single Domain Antibody
Monoclonal and polyclonal antibodies Abs are wellcorroborated tools adopted in basic biomedical research and innovative key components of numerous therapeutic platforms today on the market The vast majority of the Abs are obtained from easily accessible laboratory animals such as mice hamsters and rabbits and consist of two heavy and two light chains
Research Insights
Enhancing Drug Repositioning: A Multi-class Ensemble Model for Drug-target Interaction Prediction with Action Type Categorization
Accurate prediction of drugtarget interactions DTIs is critical for accelerating drug repositioning and reducing the cost of pharmaceutical development Most existing studies frame DTI prediction as a binary task
Case Studies
Unusual Drug Response And Hemodynamics In VA – ECMO : A Drug Case Study
Abstract Maintaining higher sedation in patients undergoing ECMO therapy is crucial Currently no definite sedation strategy has been proposed in the literature as the pharmacokinetics of the medications in these patients is still not clear We would like to report a case of a patient with uncontrollable diverse clinical response to medications during arteriovenou
Techno Trends
First of its Kind IMBRUVICA® (ibrutinib) Developed for the Treatment of Chronic Graft-Versus-Host Disease (cGVHD)
The Janssen Pharmaceutical Companies of Johnson Johnson developed IMBRUVICA ibrutinib the first and only treatment for Chronic GraftVersusHost Disease in pediatric patients IMBRUVICA is the only BTKi treatment approved by FDA applicable for individuals with one year and older with chronic graftversushost disease cGVHD regardless of one or more systemic therapy failur...
White Papers
Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches
In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS
TOP ARTICLES
Commissioning the 505(b)(2) Pathways in Hastening the Clinical Translation of Various Drugs via Nanotechnological Approaches
Saurabh Srivastava is Associate Professor in Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad. He carries more than 15 years of profound industrial and research experience working with several Pharmaceutical R&Ds, including IPCA labs, Wockhardt research centre and Dr. Reddy’s Laboratories for development and commercialisation of various NDA and ANDA based products for different regulated markets. He is actively involved in execution of several Industrial and Govt. aided research projects for establishment of novel differentiated (505 b 2) product development. He has 02 Commercial Products, 10 International and National Patents, 01 Edited book, 10 Book chapters along with 25 research publications in Journals of International repute to his credit.
Saurabh Shah is currently pursuing his Ph.D. from National Institute of Pharmaceutical Education and Research, Hyderabad. He has published 2 research papers, 4 review articles and 2 book chapters in renowned journals. His research focus lies in hastening the clinical translation of nanomedicine-based products from bench to bedside. He has also been involved in numerous industry research and development projects from laboratory to pilot scale up.
Advancing Automation and Digitalization in the Industrial Microbiology Workflow
Brad is Head of Biomonitoring Strategic Initiatives, which includes development and execution of the Digital strategy in Robotics & Automation, eBusiness, Informatics and the Biomonitoring Ecosystem. Throughout his 10 years at the company, Brad has been engaged in Commercial, Operation and Strategy with regional and global focus.
Endocrine Disrupting Compounds (EDCs)
Sintu Kumar Samanta has been working as an Assistant professor in IIIT Allahabad, India. He did Ph.D. and post-doctoral research from IIT Kharagpur and IISc Bangalore, India respectively. He is working in the area of Biochemistry and Nanobiotechnology. He published research work in several international journals and filed one Indian patent.
Pavan Kumar Gautamis presently working as a Post-Doctoral Fellow in the Department of Applied Sciences at IIIT Allahabad, India. He obtained Ph.D. from the University of Allahabad, India. His area of research is synthesis of nanoparticles for water remediation. He published his research work in many international journals.
Evolution of eCTD from version 1 to 4
Gouspasha is a seasoned professional with 12 years of experience in the pharmaceutical industry, specializing in eCTD (Electronic Common Technical Document) publishing and submission. With a strong focus on regulatory compliance and efficient document management, Gouspasha ensures seamless and timely submissions. Dedicated to maintaining the highest standards of quality and accuracy, Gouspasha remains committed to staying current with evo0lving industry trends and regulatory requirements.
Novel Developments in Drug Delivery Systems
Saina Bijanzadeh is a chemist specializing in nanomaterial-based drug delivery and biomedical applications. She has research experience in nanoparticle synthesis, MOF platforms, and drug release systems, with published work in international journals. Her interests focus on innovative therapeutic delivery strategies and interdisciplinary pharmaceutical and bio(medical)engineering research.
press releasesRead more...
Sino Biopharmaceutical Limited Unveils New Global Brand, SBP Group, to Accelerate International Expansion
Sino Biopharmaceutical Limited HKEX a leading innovationdriven pharmaceutical company in China announced the launch of its new global brand SBP Group during its interim results meeting
For the Treatment of Resectable Non-Small Cell Lung Cancer with Neoadjuvant OPDIVO in Combination with Chemotherapy Followed by Surgery and Adjuvant Single-Agent OPDIVO
Ono Pharmaceutical Co Ltd Headquarters Osaka Japan President and COO Toichi Takino Ono today announced that Ono Pharma Taiwan Co Ltd Taipei Taiwan OPTW a Taiwanese subsidiary of Ono received
Syneos Health Advances AI-Powered Clinical Ecosystem to Optimize Trial Performance and Speed Decision-Making
Syneos Health a leading fully integrated biopharmaceutical solutions organization today announced the continued advancement of its AI ecosystem a unified enterprise approach that embeds artificial intelligence
U.S. FDA Accepts Teva’s New Drug Application (NDA) and Grants Priority Review for Ecopipam, a First-in-Class Investigational Therapy for Pediatric Patients with Tourette Syndrome
Teva Pharmaceuticals a US affiliate of Teva Pharmaceutical Industries Ltd NYSE and TASE TEVA today announced that the US Food and Drug Administration FDA accepted the New Drug Application NDA for ecopipam
GSK's Blenrep (belantamab mafodotin) combinations approved in Singapore for treatment of relapsed/refractory multiple myeloma
GSK Singapore today announced that the Singapore Health Sciences Authority HSA has approved Blenrep for the treatment of adults with relapsed or refractory multiple myeloma in combination with bortezomib plus dexamethasone
Harbour BioMed Announces NMPA Approval of IND Application for HBM7004 for the Treatment of Advanced Solid Tumors
Harbour BioMed the Company HKEX a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology oncology and other disease areas
EventsRead more...
19 - 21
Aug 2026ISPE Singapore Conference & Exhibition 2026
Suntec Singapore
20 - 21
Aug 2026Pharmaceutical Formulations 2026
London, UK
20 - 21
Aug 2026Novel Drug Delivery Systems 2026
London, UK
20 - 21
Aug 2026Advanced Clinical Research 2026
London, UK
25 - 27
Aug 2026CPHI Korea 2026
COEX, Seoul, Korea
26 - 27
Aug 2026BIOMEDevice 2026
Boston Convention & Exhibition...
03 - 05
Sep 20265th MENA Congress for Rare Diseases 2026
Beach Rotana Hotel, Abu Dhabi,...
14 - 15
Sep 202616th American DDF Summit
Omni Boston Hotel at the Seapo...
LATEST NEWSRead more...
Lotus Pharmaceutical Receives PMDA Approval for Generic Pomalidomide Capsules in Japan
Lotus Pharmaceutical Co Ltd Taiwan Stock Exchange has received marketing approval in Japan for its generic pomalidomide capsules in mg mg mg and mg strengths following a review
Ultragenyx Receives U.S. FDA Approval for GENGLYCOS Gene Therapy for Glycogen Storage Disease Type Ia
Ultragenyx Pharmaceutical Inc NASDAQ RARE has received accelerated approval from the US Food and Drug Administration FDA for GENGLYCOS pariglasgene brecaparvovecopnr also known as DTX for adults and children aged eight years and older with glycogen storage disease type Ia GSDIa
Consano Bio receives FDA Fast Track designation for C-1101 in chronic sciatica
Consano Bio has received Fast Track designation from the US Food and Drug Administration FDA for C its lead investigational plateletderived biologic being developed to treat chronic painful lumbosacral radiculopathy LSR commonly known as chronic sciatica
Piramal Pharma completes acquisition of controlling stake in Yapan Bio
Piramal Pharma Limited has completed the acquisition of an additional stake in Yapan Bio Private Limited a Hyderabadbased contract development and manufacturing organisation CDMO specialising in vaccines and biologics
TCS launches Agentic AI platform to transform drug development
Tata Consultancy Services TCS a global IT services consulting and business solutions company has launched TCS ADD AgentHub an enterpriseready AI platform designed to support the use of agentic AI across drug development
Tagomics introduces LiquiPath, a cfDNA-based blood test for multi-organ drug safety monitoring
Tagomics Ltd a precision medicine company has launched LiquiPath a crossspecies multiorgan liquid pathology platform designed for noninvasive drug safety monitoring The platform is intended for use